Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

A legfontosabb adatok

Ki végzi
BioTissue Holdings, Inc
Hol
Boston, Circleville, Dallas, DeLand, Delray Beach, Guntersville, Houston, Los Angeles, Mather, O'Fallon, Palmdale, Reno, Tucson, Westwood és Whittier (Egyesült Államok)Mind a 16 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
106 fő vett részt
Kezdés
2020. nov. 20.
Befejezés
2025. márc. 24.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • TTAX01
  • Standard care
A regiszteradat frissítve
2025. április 1.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • The subject has signed the informed consent form
  • The subject is male or female, at least 18 years of age inclusive at the date of Screening
  • The subject has confirmed diagnosis of Type I or Type II diabetes
  • The subject's index ulcer is located on the plantar surface, inter digital, heel, lateral or medial surface of the foot
  • The subject has an index ulcer with visible margins having an area ≤ 12.0 cm2 when measured by the electronic measuring device at Screening
  • The subject's index ulcer extends beyond the dermis, into subcutaneous tissue with evidence of exposed bone, tendon, muscle and/or joint capsule
  • The subject presents with history, signs or symptoms leading to a clinical suspicion of osteomyelitis in the opinion of the Investigator supported by positive Probe to Bone (PTB) and any of the following: radiographic (X-ray, Magnetic Resonance Imaging (MRI), or bone scan) or evidence of bone necrosis
  • The subject has an Ankle-Brachial Index ≥ 0.7 to ≤ 1.3 or TcPO2 ≥ 40 mmHg on the dorsum of the affected foot, or Great Toe Pressure ≥ 50 mmHg
  • The subject is under the care of a physician for the management of Diabetes Mellitus
  • The subject is willing to return for all mandatory visits as defined in the protocol
  • The subject is willing to follow the instructions of the trial Investigator

Ki nem vehet részt

  • The subject has been on oral steroid use of > 7.5 mg daily for greater than seven (7) consecutive days in 30 days before Screening
  • The subject has been on parenteral corticosteroids, or any cytotoxic agents for seven consecutive days in the period of 30 days before Screening
  • The subject is currently taking the type 2 diabetes medicine canagliflozin (Invokana™, Invokamet™, Invokamet XR™)
  • The subject is a woman of child-bearing potential who is unwilling to avoid pregnancy or use an appropriate form of birth control (adequate birth control methods are defined as: topical, oral, implantable, or injectable contraceptives; spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine contraceptive device; or surgical sterilization of partner)
  • The subject has had previous use of NEOX®, CLARIX®, or TTAX01 applied to the index ulcer
  • The subject's index ulcer is primarily located on the dorsal surface of the foot
  • The subject's index ulcer can be addressed by primary closure through the completion of the initial or staged surgical procedure
  • The subject has malignancy or a history of cancer, other than non-melanoma skin cancer, in five years before Screening
  • The subject has an allergy to primary or secondary dressing materials used in this trial
  • The subject has an allergy to glycerol
  • The subject's index ulcer is over an acute Charcot deformity
  • Per Investigator's discretion the subject is not appropriate for inclusion in the trial, e.g., undergoing surgical treatments listed in the protocol or the subject currently has sepsis, i.e., life-threatening organ dysfunction caused by a dysregulated host response to infection
  • The subject has a glycated hemoglobin A1c (HbA1c) level of > 12% †
  • The subject has a contralateral major amputation of the lower extremity
  • The subject is pregnant
  • The subject is a nursing mother
  • The subject is unable to sustain off-loading as defined by the protocol

Helyszínek itt: Egyesült Államok

  • Beth Israel Deaconess Medical CenterBoston, Egyesült Államok
  • Cutting Edge Research, LLCCircleville, Egyesült Államok
  • University of Texas Southwestern Medical CenterDallas, Egyesült Államok
  • Midland Florida Clinical Research CenterDeLand, Egyesült Államok
  • Delray Physician Care CenterDelray Beach, Egyesült Államok
  • Lakeview Clinical ResearchGuntersville, Egyesült Államok
  • Advantage Foot Care of HoustonHouston, Egyesült Államok
  • Biolife Genetics ResearchHouston, Egyesült Államok
  • Clemente Clinical ResearchLos Angeles, Egyesült Államok
  • VA Northern California Health Care SystemMather, Egyesült Államok
  • Gateway Clinical Trials, LLCO'Fallon, Egyesült Államok
  • CureCentricPalmdale, Egyesült Államok
  • Reno Orthopedic ClinicReno, Egyesült Államok
  • Banner University Medical Center - TucsonTucson, Egyesült Államok
  • Curalta Foot and AnkleWestwood, Egyesült Államok
  • PIH HealthWhittier, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone. This second confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.

A vizsgálat 2 csoportja

  • TTAX01A vizsgált kezelés

    TTAX01 plus standard of care

    Kezelés: TTAX01 és Standard care

  • ControlEgyéb csoport

    Standard care alone

    Kezelés: Standard care

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multicenter Phase 3 Confirmatory Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)
A regiszteradat frissítve
2025. április 1.